Zoetis offers defensive animal health value after a sharp selloff

Conviction: 68% · Horizon: 3Y · 2026-05-26
A resilient pet medicine franchise can justify a modest valuation despite slower growth

Zoetis combines pricing power, stable margins, strong companion animal exposure, and buyback-supported EPS growth. A valuation near 13 times earnings may be reasonable if the recent decline in US companion animal revenue proves temporary rather than structural.

Instrument Side Target Reason
ZTS Long We believe a global animal health leader with defensible pet medicine economics, recurring veterinary demand, stable margins, and high-single-digit EPS growth can rerate if revenue weakness normalizes and debt-funded buybacks remain manageable.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.